View Cart  

Sanofi, Regeneron Commence Patient Recruitment in Phase III CVOT

A A
Sanofi and Regeneron Pharmaceuticals have commenced patient recruitment in a Phase III cardiovascular outcomes trial (CVOT) to test SAR236553/REGN727, designed to lessen low-density lipoprotein cholesterol levels.
Pharmaceutical Business Review